Why Wegovy stays active in your system for a full week

Picture the morning after your last injection

You injected Wegovy six days ago. You have not eaten much for breakfast because your appetite is still noticeably quieter than it was before you started treatment. That is semaglutide still at work. Unlike many medicines that need to be taken every few hours to stay above a useful concentration in the blood, semaglutide has been engineered to linger, and it does so by design rather than by chance.

When semaglutide is injected under the skin, it does not rush straight into the bloodstream. It is absorbed slowly from the subcutaneous tissue, reaching its peak concentration roughly one to three days after the injection. From that peak, levels fall gradually over the remaining days of the week. By the time your next injection is due, there is still enough circulating semaglutide to keep GLP-1 receptors partially activated. You can read more about that peak moment (and what it means in practice) on our page covering when Wegovy peaks in your system.

This slow, steady profile is why once-weekly dosing works at all. The NHS semaglutide medicines page describes the once-weekly injection schedule, reflecting the pharmacokinetic properties that make that schedule possible.

What actually slows semaglutide down inside the body

Natural GLP-1, the gut hormone semaglutide mimics, disappears from the bloodstream within minutes. Semaglutide lasts days rather than minutes because chemists at Novo Nordisk made three key structural changes to the natural hormone.

First, a fatty-acid side chain was attached to the semaglutide molecule. This chain causes semaglutide to bind reversibly to albumin, the most abundant protein in human blood. While bound to albumin, semaglutide is shielded from the enzyme (dipeptidyl peptidase-4) that rapidly degrades natural GLP-1. Second, a small amino-acid substitution makes the molecule more resistant to that same enzyme in the first place. Third, the albumin binding also slows the rate at which semaglutide is filtered out by the kidneys.

The result is a plasma half-life of roughly seven days. That means that one week after an injection, about half the dose is still present; two weeks out, about a quarter. This is why, if you want to understand how long semaglutide remains detectable after stopping treatment, the full clearance story takes considerably longer than a week, our page on when Wegovy leaves your system covers that in detail.

For people wondering whether levels accumulate over successive doses, the answer is yes, up to a point. The concept of whether Wegovy builds up in your system explains how steady-state is reached after roughly four to five weeks and why appetite suppression often becomes more consistent from that point on.

What this means week to week, and why timing still matters

The long half-life offers genuine practical advantages. If your injection day falls on a Monday and a bank holiday disrupts your routine, missing by a day or two does not cause your semaglutide levels to collapse in the way skipping a daily pill might. The SmPC guidance (available via the Medicines Compendium) addresses flexibility around missed doses, always follow that, or ask your prescriber, rather than guessing.

That said, consistency across the weeks matters more than most people expect. Because the therapeutic effect builds as the drug accumulates to steady state, erratic timing delays that build-up. Think of it like filling a bath with the tap only half on, steady flow gets you there; stopping and starting keeps you waiting. If you are starting treatment for the first time, our overview of how Wegovy works across a week explains the day-by-day picture in straightforward terms.

One practical aside worth mentioning: payday timing, Monday order deadlines, or a holiday away from home can all disrupt when you collect your next pen. Planning ahead so your supply arrives before you run out matters, a gap of more than two weeks at steady state may mean restarting from a lower dose, which is something to discuss with your prescriber rather than decide alone.

For a broader look at what semaglutide is and how it is licensed in the UK, the semaglutide overview on the nume site is a useful starting point. If you are exploring whether Wegovy might be appropriate for your situation, a clinical consultation is the right place to take that question.

Why a long-acting medicine still needs clinical oversight

The fact that semaglutide stays in your system for a week does not mean it is self-managing. Side effects (nausea, changes in digestion, rare but serious symptoms such as severe abdominal pain) can appear at any point in the dosing cycle, not only around the time of the injection. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk allows patients and clinicians to report unexpected reactions, and doing so helps build the safety picture for everyone on these medicines.

Dose increases also require review. Moving up through the 0.25mg, 0.5mg, 1.0mg, 1.7mg and 2.4mg schedule is a clinical decision, not a calendar event, because the rate at which your system adjusts to higher concentrations of semaglutide varies from person to person. At nume, a GPhC-registered prescriber reviews every order before anything is dispatched, that review applies to first prescriptions and to every repeat, because a medicine that lingers in your system for a week deserves a clinician who checks in more often than that.

If cost is a factor in your thinking, it is worth looking honestly at what different providers include in their pricing, our Wegovy cost guide explains what the market actually looks like and what to watch for. When you are ready to talk to a prescriber about whether treatment is right for you, check your eligibility with our clinical team.